<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication" xmlns:n2016="http://publications.europa.eu/resource/schema/ted/2016/nuts" xsi:schemaLocation="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication TED_EXPORT.xsd" VERSION="R2.0.9.S03.E01" DOC_ID="426110-2019" EDITION="2019175"><TECHNICAL_SECTION><RECEPTION_ID>19-438193-001</RECEPTION_ID><DELETION_DATE>20191218</DELETION_DATE><FORM_LG_LIST>EN </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="http://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>175</NO_OJ><DATE_PUB>20190911</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2019/S 175-426110</NO_DOC_OJS><URI_LIST><URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:426110-2019:TEXT:EN:HTML</URI_DOC></URI_LIST><LG_ORIG>EN</LG_ORIG><ISO_COUNTRY VALUE="UK"/><IA_URL_GENERAL>https://nhsengland.bravosolution.co.uk</IA_URL_GENERAL><ORIGINAL_CPV CODE="33600000">Pharmaceutical products</ORIGINAL_CPV><n2016:PERFORMANCE_NUTS CODE="UKI">LONDON</n2016:PERFORMANCE_NUTS><n2016:CA_CE_NUTS CODE="UK">UNITED KINGDOM</n2016:CA_CE_NUTS><n2016:TENDERER_NUTS CODE="UK">UNITED KINGDOM</n2016:TENDERER_NUTS><VALUES><VALUE TYPE="PROCUREMENT_TOTAL" CURRENCY="GBP">503860674</VALUE></VALUES><REF_NOTICE><NO_DOC_OJS>2019/S 050-114370</NO_DOC_OJS></REF_NOTICE></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20190909</DS_DATE_DISPATCH><AA_AUTHORITY_TYPE CODE="1">Ministry or any other national or federal authority</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="7">Contract award notice</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="1">Open procedure</PR_PROC><RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION><TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID><AC_AWARD_CRIT CODE="2">The most economic tender</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES><HEADING>01B03</HEADING><INITIATOR>01</INITIATOR></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="BG"><TI_CY>Обединено кралство</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Фармацевтични продукти</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Spojené království/Velká Británie</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Léčivé přípravky a zdravotnické prostředky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DA"><TI_CY>Forenede Kongerige, Det</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Lægemidler</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>das Vereinigte Königreich</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Arzneimittel</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Ηνωμένο Βασίλειο</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Φαρμακευτικά προϊόντα</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>United Kingdom</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Productos farmacéuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Suurbritannia / Ühendkuningriik</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Ravimid</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Yhdistynyt kuningaskunta</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaseuttiset tuotteet</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Royaume-Uni</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produits pharmaceutiques</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Ríocht Aontaithe, an</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Pharmaceutical products</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Ujedinjena Kraljevina</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Egyesült Királyság</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Gyógyszerészeti termékek</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Regno Unito</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Prodotti farmaceutici</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmacijos produktai</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Apvienotā Karaliste</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmācijas izstrādājumi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>Ir-Renju Unit</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Prodotti farmaċewtiċi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Verenigd Koninkrijk</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutische producten</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Zjednoczone Królestwo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produkty farmaceutyczne</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Reino Unido</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produtos farmacêuticos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Regatul Unit</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Produse farmaceutice</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Spojené kráľovstvo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmaceutické výrobky</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Združeno kraljestvo</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Farmacevtski proizvodi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Förenade kungariket</TI_CY><TI_TOWN>Runcorn</TI_TOWN><TI_TEXT><P>Läkemedel</P></TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="EN">NHS Commissioning Board (operating under the name of NHS England)</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><F03_2014 CATEGORY="ORIGINAL" FORM="F03" LG="EN"><LEGAL_BASIS VALUE="32014L0024"/><CONTRACTING_BODY><ADDRESS_CONTRACTING_BODY><OFFICIALNAME>NHS Commissioning Board (operating under the name of NHS England)</OFFICIALNAME><ADDRESS>NHS England, Rutland House, 2nd Floor</ADDRESS><TOWN>Runcorn</TOWN><POSTAL_CODE>WA7 2ES</POSTAL_CODE><COUNTRY VALUE="UK"/><E_MAIL>Katie.noonan@nhs.net</E_MAIL><n2016:NUTS CODE="UK"/><URL_GENERAL>https://nhsengland.bravosolution.co.uk</URL_GENERAL><URL_BUYER>https://nhsengland.bravosolution.co.uk</URL_BUYER></ADDRESS_CONTRACTING_BODY><CENTRAL_PURCHASING/><CA_TYPE VALUE="MINISTRY"/><CA_ACTIVITY VALUE="HEALTH"/></CONTRACTING_BODY><OBJECT_CONTRACT><TITLE><P>NHS Framework for the NHS London Region, Branded Medicines – Tranche B, Cytokine Modulators and Other Monoclonal Antibodies and Antiretrovirals</P></TITLE><CPV_MAIN><CPV_CODE CODE="33600000"/></CPV_MAIN><TYPE_CONTRACT CTYPE="SUPPLIES"/><SHORT_DESCR><P>CM/PHR/16/5515/01 — 1.9.2019 to 31.8.2021 – NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.</P><P>CM/PHR/16/5515/02 — 1.9.2019 to 31.8.2020 — NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.</P><P>CM/PHR/16/5515/03 — 1.9.2019 to 31.8.2020 – NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.</P></SHORT_DESCR><VAL_TOTAL CURRENCY="GBP">503860674</VAL_TOTAL><LOT_DIVISION/><OBJECT_DESCR ITEM="1"><TITLE><P>NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an Option to extend (at the Authority’s Discretion) for a Period or Periods Up to a Total of 24 Months</P></TITLE><LOT_NO>1</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UKI"/><MAIN_SITE><P>Please refer to schedule 8 of the framework agreement.</P></MAIN_SITE><SHORT_DESCR><P>CM/PHR/16/5515/01 — 1.9.2019 to 31.8.2021 – NHS Framework for the NHS London Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.</P><P>Products associated with the lots are listed on document No 05 of the Invitation to offer.</P><P>Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.</P><P>There is no restriction on the number of products that bidders can offer for, or be awarded.</P><P>The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.</P><P>The framework may also be used by private sector contractors and agents working on behalf of the above.</P></SHORT_DESCR><AC><AC_QUALITY><AC_CRITERION>Price is not the only award criterion and all criteria are stated only in the procurement documents</AC_CRITERION><AC_WEIGHTING>1</AC_WEIGHTING></AC_QUALITY><AC_COST><AC_CRITERION>Price is not the only award criterion and all criteria are stated only in the procurement documents</AC_CRITERION><AC_WEIGHTING>1</AC_WEIGHTING></AC_COST></AC><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR><OBJECT_DESCR ITEM="2"><TITLE><P>NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and Other Monoclonal Antibodies with an Option to extend (at the Authority’s Discretion) for a Period</P></TITLE><LOT_NO>2</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UKI"/><SHORT_DESCR><P>CM/PHR/16/5515/02 — 1.9.2019 to 31.8.2020 — NHS Framework for the NHS London Region, Branded Medicines – Annual Tranche — Cytokine Modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.</P><P>Products associated with the lots are listed on document No 05 of the Invitation to offer.</P><P>Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.</P><P>There is no restriction on the number of products that bidders can offer for, or be awarded.</P><P>The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.</P><P>The framework may also be used by private sector contractors and agents working on behalf of the above.</P></SHORT_DESCR><AC><AC_QUALITY><AC_CRITERION>Price is not the only award criterion and all criteria are stated only in the procurement documents</AC_CRITERION><AC_WEIGHTING>1</AC_WEIGHTING></AC_QUALITY><AC_COST><AC_CRITERION>Price is not the only award criterion and all criteria are stated only in the procurement documents</AC_CRITERION><AC_WEIGHTING>1</AC_WEIGHTING></AC_COST></AC><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR><OBJECT_DESCR ITEM="3"><TITLE><P>NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an Option to extend (at the Authority’s Discretion) for a Period or Periods Up to a total of 12 Months</P></TITLE><LOT_NO>3</LOT_NO><CPV_ADDITIONAL><CPV_CODE CODE="33600000"/></CPV_ADDITIONAL><n2016:NUTS CODE="UKI"/><SHORT_DESCR><P>CM/PHR/16/5515/03 — 1.9.2019 to 31.8.2020 – NHS Framework for the NHS London Region, Branded Medicines — Antiretrovirals with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months.</P><P>Products associated with the lots are listed on document No 05 of the Invitation to offer.</P><P>Each individual National product code (NPC) pack description in each of the regions (London) is deemed to be a separate product for the application of the award criteria.</P><P>There is no restriction on the number of products that bidders can offer for, or be awarded.</P><P>The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England.</P><P>The framework may also be used by private sector contractors and agents working on behalf of the above.</P></SHORT_DESCR><AC><AC_QUALITY><AC_CRITERION>Price is not the only award criterion and all criteria are stated only in the procurement documents</AC_CRITERION><AC_WEIGHTING>1</AC_WEIGHTING></AC_QUALITY><AC_COST><AC_CRITERION>Price is not the only award criterion and all criteria are stated only in the procurement documents</AC_CRITERION><AC_WEIGHTING>1</AC_WEIGHTING></AC_COST></AC><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR></OBJECT_CONTRACT><PROCEDURE><PT_OPEN/><FRAMEWORK/><CONTRACT_COVERED_GPA/><NOTICE_NUMBER_OJ>2019/S 050-114370</NOTICE_NUMBER_OJ></PROCEDURE><AWARD_CONTRACT ITEM="1"><AWARDED_CONTRACT><DATE_CONCLUSION_CONTRACT>2019-07-05</DATE_CONCLUSION_CONTRACT><TENDERS><NB_TENDERS_RECEIVED>33</NB_TENDERS_RECEIVED><NB_TENDERS_RECEIVED_EMEANS>33</NB_TENDERS_RECEIVED_EMEANS></TENDERS><CONTRACTORS><NO_AWARDED_TO_GROUP/><CONTRACTOR><ADDRESS_CONTRACTOR><OFFICIALNAME>NHS Comissioning Boards (Operating under the name of NHS England)</OFFICIALNAME><TOWN>Runcorn</TOWN><COUNTRY VALUE="UK"/><n2016:NUTS CODE="UK"/></ADDRESS_CONTRACTOR><NO_SME/></CONTRACTOR></CONTRACTORS><VALUES><VAL_TOTAL CURRENCY="GBP">503860674</VAL_TOTAL></VALUES></AWARDED_CONTRACT></AWARD_CONTRACT><COMPLEMENTARY_INFO><INFO_ADD><P>Awarded suppliers:</P><P>— AbbVie Ltd,</P><P>— Amgen Ltd,</P><P>— Astellas Pharma Ltd,</P><P>— Aventis Pharma Ltd Tranding as Sanofi,</P><P>— Biogen Idec UK Ltd,</P><P>— Bristol-Myers Squibb Pharmaceuticals Ltd,</P><P>— Daiichi Sankyo UK Ltd,</P><P>— ELI Lilly and Company Ltd,</P><P>— Ferring Pharmaceutical,</P><P>— Gedeon Richter UK Ltd,</P><P>— MYLAN UK Healthcare Ltd,</P><P>— Gilead Sciences Ltd,</P><P>— Ipsen Ltd,</P><P>— Janssen Cilag Ltd,</P><P>— Fannin UK Ltd T/A Kent Pharmaceuticals Ltd,</P><P>— LEO Pharma,</P><P>— Merck Serono Ltd,</P><P>— Merck Sharp and Dohme (MSD),</P><P>— Napp Pharmaceuticals Ltd,</P><P>— Novartis Pharmaceutical UK Ltd,</P><P>— Novo Nordisk Ltd,</P><P>— Pfizer Ltd,</P><P>— Pharmasure Ltd,</P><P>— Roche Products Ltd,</P><P>— ROVI Biotech Ltd,</P><P>— Sandoz Ltd,</P><P>— Takeda UK Ltd,</P><P>— Techdow Pharma England Ltd,</P><P>— UCB Pharma Ltd,</P><P>— ViiV Healthcare Ltd.</P></INFO_ADD><ADDRESS_REVIEW_BODY><OFFICIALNAME>The NHS Commissioning Board (Operating Under the Name of NHS England)</OFFICIALNAME><ADDRESS>NHS England, Rutland House, Second Floor</ADDRESS><TOWN>Runcorn</TOWN><POSTAL_CODE>WA7 2ES</POSTAL_CODE><COUNTRY VALUE="UK"/></ADDRESS_REVIEW_BODY><DATE_DISPATCH_NOTICE>2019-09-09</DATE_DISPATCH_NOTICE></COMPLEMENTARY_INFO></F03_2014></FORM_SECTION></TED_EXPORT>